User profiles for Michelle A. Rudek
Michelle RudekProfessor of Oncology and Medicine, Johns Hopkins University Verified email at jhmi.edu Cited by 12177 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non–small cell lung cancer
…, N Franco, B Lee, S Tsai, IE Delgado, MA Rudek… - Cancer discovery, 2011 - AACR
Epigenetic alterations are strongly associated with the development of cancer. We conducted
a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat, inhibitors …
a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat, inhibitors …
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
…, M Grever, O Galm, T Dauses, JE Karp, MA Rudek… - Cancer research, 2006 - AACR
Optimal reexpression of most genes silenced through promoter methylation requires the
sequential application of DNA methyltransferase inhibitors followed by histone deacetylase …
sequential application of DNA methyltransferase inhibitors followed by histone deacetylase …
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
…, ML Alattar, MR Grunwald, MA Rudek… - Blood, The Journal …, 2013 - ashpublications.org
Patients received 5-azacytidine (AZA) 75 mg/m 2 intravenously daily for 7 days and sorafenib
400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-…
400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-…
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance
…, RR De Haas, H Dekker, RJ Honeywell, MA Rudek… - Clinical Cancer …, 2011 - AACR
Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We analyzed …
important clinical problem, but its underlying mechanisms are largely unknown. We analyzed …
[PDF][PDF] A targeting modality for destruction of RNA polymerase I that possesses anticancer activity
…, R Trivedi, MS Moubarek, HM Moore, B Bai, MA Rudek… - Cancer cell, 2014 - cell.com
We define the activity and mechanisms of action of a small molecule lead compound for
cancer targeting. We show that the compound, BMH-21, has wide and potent antitumorigenic …
cancer targeting. We show that the compound, BMH-21, has wide and potent antitumorigenic …
[HTML][HTML] Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV working group
TS Uldrick, G Ison, MA Rudek, A Noy… - Journal of clinical …, 2017 - ncbi.nlm.nih.gov
Purpose People with HIV are living longer as a result of effective antiretroviral therapy. Cancer
has become a leading cause of morbidity and mortality in this patient population. However…
has become a leading cause of morbidity and mortality in this patient population. However…
The rising challenge of non–AIDS-defining cancers in HIV-infected patients
JF Deeken, A Tjen-A-Looi, MA Rudek… - Clinical infectious …, 2012 - academic.oup.com
Since the advent of HAART, patients with HIV infection have seen a significant improvement
in their morbidity, mortality, and life expectancy. The incidence of AIDS-defining illnesses, …
in their morbidity, mortality, and life expectancy. The incidence of AIDS-defining illnesses, …
Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer
Curcumin or diferuloylmethane is a yellow polyphenol extracted from the rhizome of turmeric
(Curcuma longa). A large volume (several hundreds) of published reports has established …
(Curcuma longa). A large volume (several hundreds) of published reports has established …
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration‐resistant …
Background. The antifungal drug itraconazole inhibits angiogenesis and Hedgehog signaling
and delays tumor growth in murine prostate cancer xenograft models. We conducted a …
and delays tumor growth in murine prostate cancer xenograft models. We conducted a …
Targeting DDX 3 with a small molecule inhibitor for lung cancer therapy
…, P van der Groep, A Kondaskar, MA Rudek… - EMBO molecular …, 2015 - embopress.org
Lung cancer is the most common malignancy worldwide and is a focus for developing targeted
therapies due to its refractory nature to current treatment. We identified a RNA helicase, …
therapies due to its refractory nature to current treatment. We identified a RNA helicase, …